These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25481459)

  • 1. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2015 Feb; 45(2):161-7. PubMed ID: 25481459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
    Rodriguez CA; Agudelo M; Aguilar YA; Zuluaga AF; Vesga O
    PLoS One; 2016; 11(5):e0155806. PubMed ID: 27191163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA.
    Jones RN; Sader HS; Flamm RK; Watters AA
    Diagn Microbiol Infect Dis; 2013 May; 76(1):110-2. PubMed ID: 23490010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin).
    Thamlikitkul V; Tiengrim S; Chalermsri C; Sae-Jong R; Suddhichupaiboon S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S196-202. PubMed ID: 21721447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
    Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
    Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
    Hyatt JM; Nix DE; Stratton CW; Schentag JJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1711-6. PubMed ID: 7486906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis.
    Frei CR; Hampton SL; Burgess DS
    Clin Ther; 2006 Jul; 28(7):1035-40. PubMed ID: 16990081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    PLoS One; 2019; 14(2):e0211096. PubMed ID: 30726248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.
    Vesga O; Agudelo M; Salazar BE; Rodriguez CA; Zuluaga AF
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3271-9. PubMed ID: 20547818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.
    Agudelo M; Vesga O
    Antimicrob Agents Chemother; 2012 May; 56(5):2659-65. PubMed ID: 22330928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    BMC Infect Dis; 2010 Jun; 10():153. PubMed ID: 20525378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of piperacillin-tazobactam.
    Hayashi Y; Roberts JA; Paterson DL; Lipman J
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
    Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
    Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
    Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.
    Jones RN; Fritsche TR; Moet GJ
    Diagn Microbiol Infect Dis; 2008 May; 61(1):76-9. PubMed ID: 18221852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
    Strayer AH; Gilbert DH; Pivarnik P; Medeiros AA; Zinner SH; Dudley MN
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2351-6. PubMed ID: 7840569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
    Shea KM; Cheatham SC; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.